001     127706
005     20240228140945.0
024 7 _ |a 10.1038/nm.3852
|2 doi
024 7 _ |a pmid:25915831
|2 pmid
024 7 _ |a pmc:PMC4450999
|2 pmc
024 7 _ |a 1078-8956
|2 ISSN
024 7 _ |a 1546-170X
|2 ISSN
024 7 _ |a altmetric:3948597
|2 altmetric
037 _ _ |a DKFZ-2017-03729
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Vicuña, Lucas
|b 0
245 _ _ |a The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase.
260 _ _ |a New York, NY
|c 2015
|b Nature America Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521641049_922
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Neuropathic pain is a major, intractable clinical problem and its pathophysiology is not well understood. Although recent gene expression profiling studies have enabled the identification of novel targets for pain therapy, classical study designs provide unclear results owing to the differential expression of hundreds of genes across sham and nerve-injured groups, which can be difficult to validate, particularly with respect to the specificity of pain modulation. To circumvent this, we used two outbred lines of rats, which are genetically similar except for being genetically segregated as a result of selective breeding for differences in neuropathic pain hypersensitivity. SerpinA3N, a serine protease inhibitor, was upregulated in the dorsal root ganglia (DRG) after nerve injury, which was further validated for its mouse homolog. Mice lacking SerpinA3N developed more neuropathic mechanical allodynia than wild-type (WT) mice, and exogenous delivery of SerpinA3N attenuated mechanical allodynia in WT mice. T lymphocytes infiltrate the DRG after nerve injury and release leukocyte elastase (LE), which was inhibited by SerpinA3N derived from DRG neurons. Genetic loss of LE or exogenous application of a LE inhibitor (Sivelastat) in WT mice attenuated neuropathic mechanical allodynia. Overall, we reveal a novel and clinically relevant role for a member of the serpin superfamily and a leukocyte elastase and crosstalk between neurons and T cells in the modulation of neuropathic pain.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Acute-Phase Proteins
|2 NLM Chemicals
650 _ 7 |a Enzyme Inhibitors
|2 NLM Chemicals
650 _ 7 |a Serpina3n protein, mouse
|2 NLM Chemicals
650 _ 7 |a Serpina3n protein, rat
|2 NLM Chemicals
650 _ 7 |a Serpins
|2 NLM Chemicals
650 _ 7 |a Leukocyte Elastase
|0 EC 3.4.21.37
|2 NLM Chemicals
700 1 _ |a Strochlic, David E
|b 1
700 1 _ |a Latremoliere, Alban
|b 2
700 1 _ |a Bali, Kiran Kumar
|0 0000-0002-9503-1402
|b 3
700 1 _ |a Simonetti, Manuela
|b 4
700 1 _ |a Husainie, Dewi
|b 5
700 1 _ |a Prokosch, Sandra
|0 P:(DE-He78)3c6157a315192b4a95e0138399b89da9
|b 6
|u dkfz
700 1 _ |a Riva, Priscilla
|b 7
700 1 _ |a Griffin, Robert S
|b 8
700 1 _ |a Njoo, Christian
|b 9
700 1 _ |a Gehrig, Stefanie
|b 10
700 1 _ |a Mall, Marcus A
|b 11
700 1 _ |a Arnold, Bernd
|0 P:(DE-He78)554abc2af2666cc3421cc0d7f6e7b6de
|b 12
|u dkfz
700 1 _ |a Devor, Marshall
|0 0000-0001-8206-3301
|b 13
700 1 _ |a Woolf, Clifford J
|b 14
700 1 _ |a Liberles, Stephen D
|b 15
700 1 _ |a Costigan, Michael
|b 16
700 1 _ |a Kuner, Rohini
|b 17
773 _ _ |a 10.1038/nm.3852
|g Vol. 21, no. 5, p. 518 - 523
|0 PERI:(DE-600)1484517-9
|n 5
|p 518 - 523
|t Nature medicine
|v 21
|y 2015
|x 1546-170X
909 C O |o oai:inrepo02.dkfz.de:127706
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)3c6157a315192b4a95e0138399b89da9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)554abc2af2666cc3421cc0d7f6e7b6de
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|2 G:(DE-HGF)POF3-300
|v Tumor immunology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT MED : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b NAT MED : 2015
920 1 _ |0 I:(DE-He78)D050-20160331
|k D050
|l Molekulare Immunologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D050-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21